COMMUNIQUÉS West-GlobeNewswire

Applied Biologics Introduces ECM Preservation Technology™ as the Proprietary Manufacturing Platform Behind XWRAP®
09/07/2026
SCOTTSDALE, Ariz., July 09, 2026 (GLOBE NEWSWIRE) -- Following the recent publication of translational research demonstrating that tissue processing methodologies can influence biologic outcomes, Applied Biologics today [...]
Xealth Launches Support for Health Systems’ CMS ACCESS Participation, Targeting Up to 5% MSSP ACO Savings
09/07/2026
The company will also connect ACCESS participants with healthcare providers, facilitating referrals through its platform SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Xealth , the leader in digital health orchestration and [...]
ENvue Medical Unveils Its First Robotic-Assisted, Artificial Intelligence, Feeding Tube Automation Tool
09/07/2026
ENvue Targeting Combined $10 Billion+ Enteral Feeding and Vascular Access Market Opportunity* ENvue Drive ™ Demonstration Marks First Step Toward a New Generation of Intelligent Bedside Procedures and Integrates ENvue’s [...]
GUERBET : Bilan semestriel du contrat de liquidité
09/07/2026
Bilan semestriel du contrat de liquidité Villepinte, le 9 juillet 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]
Cynet Releases 2026 Global AI Security Readiness Report
09/07/2026
New report shows more than half of in-house security teams want managed service providers (MSPs) involved when adopting new cybersecurity capabilities, while 60% reporting security incidents BOSTON, July 09, 2026 (GLOBE [...]
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
09/07/2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]
Heald Expands Access to AI-Powered Glucose Intelligence for Over-the-Counter CGM Users
09/07/2026
Consumers purchasing Dexcom Stelo or Abbott Lingo through Heald now receive complimentary access to AI-powered glucose insights ALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health [...]
UREVO Wins Red Dot Award 2026 for AI-Powered Wireless Recovery Boots, Recognized for Real-Time, AI-Adaptive Recovery
09/07/2026
ESSEN, July 09, 2026 (GLOBE NEWSWIRE) -- Smart wellness innovator UREVO has been named a winner of the Red Dot Award: Product Design 2026 in the Innovative Design category for its AI-Powered Wireless Recovery Boots . [...]
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
09/07/2026
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin [...]
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
09/07/2026
Cohort 1 Topline Data Expected in the Second Week of September 2026 RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a [...]
Alkeus Pharmaceuticals Announces Gildeuretinol Data Presentations During the American Society of Retina Specialists (ASRS) 44th Annual Meeting July 15 - 18
09/07/2026
CAMBRIDGE, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data from [...]
Atsena Therapeutics Selects ATSN-401 Clinical Candidate, a Potential Best-in-Class Gene Therapy for Stargardt Disease
09/07/2026
Proprietary dual-vector platform delivers full-length ABCA4, enabled by Atsena's laterally spreading AAV.SPR capsid for delivery to the central retina without foveal detachment ATSN-401 advancing in IND-enabling studies [...]
VisCardia Implants First U.S. Patient in RECOVER-HF Pivotal Trial
09/07/2026
Milestone in pivotal IDE evaluation of VisONE™ Synchronized Diaphragmatic Stimulation Therapy for symptomatic heart failure with reduced ejection fraction; FDA Breakthrough Device Designation PORTLAND, Ore., July 09, [...]
Sam’s Club® and Weight Watchers® Collaborate to Expand Access to Affordable, Holistic Wellness Experiences for Members
09/07/2026
Sam's Club Plus members may receive a complimentary three-month Weight Watchers Core membership, while all Sam's Club members can save up to 50% on select Weight Watchers programs Collaboration connects medication [...]
NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner
09/07/2026
New agreement is a significant commercial milestone and the Company’s first with its contract research organization partner Agreement expands NetraMark’s portfolio of AI-driven projects in central nervous system (CNS) [...]
New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management
09/07/2026
Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility [...]
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
09/07/2026
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position. [...]
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
09/07/2026
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

Pages